Olema Pharmaceuticals, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the Annual Meeting of Stockholders held by Olema Pharmaceuticals, Inc. on June 13, 2024. The filing details the voting outcomes for three specific proposals submitted to shareholders.
Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following matters were voted upon and approved by stockholders:
- Proposal 1: Election of Directors
- Ian Clark: 33,874,399 votes For; 12,094,961 votes Withheld.
- Sandra Horning, M.D.: 40,102,098 votes For; 5,867,262 votes Withheld.
- Gorjan Hrustanovic, Ph.D.: 44,334,757 votes For; 1,634,603 votes Withheld.
- All three nominees were elected to serve until the 2027 annual meeting.
- Proposal 2: Advisory Vote on Executive Compensation
- Result: Approved.
- Votes: 45,174,223 For; 787,068 Against; 8,069 Abstain.
- Proposal 3: Ratification of Independent Auditor
- Result: Ratified selection of Ernst & Young LLP.
- Votes: 48,366,695 For; 19,160 Against; 9,241 Abstain.
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, outlook, or specific risk factors. It references the definitive proxy statement filed on April 26, 2024, for more complete descriptions of the matters voted upon.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to calculate the percentage of votes cast for each proposal.
- Review the April 26, 2024 Proxy Statement for detailed biographies of the elected directors and executive compensation specifics.
- Note that approximately 2.4 million broker non-votes were recorded for the director election and executive compensation proposals.
- Confirm the tenure of the newly elected directors extends through the 2027 annual meeting.